Xcelerate (XCRT) investor relations material

Executive summary

• Q1 2026 net loss narrowed to $15,631 from $107,960 YoY; cash was $328,933 at March 31, while liabilities totaled $2,387,496.

• Operations focus on medical technology and virtual health services intended to extend physician access in developing countries; ASA Africa is 51%-owned.

Financial highlights

• Q1 2026 operating expenses and loss from continuing operations were $15,631, versus $47,662 of operating expenses and loss from continuing operations in Q1 2025.

• Q1 2026 cash declined to $328,933 from $363,064 at Dec. 31, 2025; total assets were $328,933 and total liabilities were $2,387,496.

• Q1 2026 net cash used in operating activities was $19,131; Q1 2025 net cash provided was $28,325, including discontinued operations.

Outlook and guidance

• Substantial doubt about going concern reflects accumulated deficit of $11,733,695, negative working capital of $2,058,536, and expected cash needs exceeding operating cash flow.

• Additional funding is needed; alternative financing is being explored, with possible private placements, securities sales, short-term loans, and stock compensation for consulting where feasible.